PACTR202112664251086尚未招募未知
Consumer Panel
niversity of Pennsylvania0 个研究点目标入组 550 人开始时间: 2021年11月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)(—)
- 性别
- All
入选标准
- •The inclusion criteria will be different for healthcare workers and care recipients.
- •Inclusion criteria for healthcare workers:
- •1. Based at selected private or public health facilities
- •2. Cadre of staff can include doctors, nurses, community health workers, outreach teams, HTS counsellors, data capturers and admin clerks
- •3. Willing to engage with the recruiter and be part of the consumer panel
- •4. Has access to a mobile phone
- •5. Age =18 years old
- •Inclusion criteria for care recipients accessing health facilities for routine care:
- •1. Attending the selected private or public health facilities and presenting at key entry points (eg. family planning, chronic section, patients presenting for HIV testing in the HTS counsellor’s room, people living with HIV who are on ART, etc) for routine services
- •2. Willing to engage with the recruiter at the facility and interested in being part of the consumer panel
- •3. Have access to a mobile phone
- •4. Age =18 years old
- •5. Able to communicate in one of the study approved languages
排除标准
- •The exclusion criteria will be different for healthcare workers and care recipients.
- •Exclusion criteria for healthcare workers:
- •1. Refuse to sign the written informed consent and choose not to participate
- •2. Less than 3 months of work experience at the selected health facility
- •3. Does not provide any HIV related care
- •Exclusion criteria for participants accessing health facilities for routine care:
- •1. Refuse to sign the written informed consent and choose not to participate
研究者
相似试验
招募中
不适用
A MULTICENTER, D OUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF H.P. ACTHAR® GEL IN THE TREATMENT OF SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS-G122 Motor neuron diseaseG122Motor neuron diseasePER-007-18Mallinckrodt ARD Inc,
进行中(未招募)
不适用
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS FOR 4-WEEKS.Type 2 diabetes mellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitusEUCTR2006-006768-53-BEPfizer Global Research & Development
进行中(未招募)
1 期
A DOUBLE-BLIND, PARALLEL GROUP, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CIRCADIN® 2MG IN THE IMPROVEMENT OF SLEEP QUALITY IN PATIENTS WITH INSOMNIA AGED 55-80 YEARS.EUCTR2004-000914-37-GBeurim Pharmaceuticals (1991) Ltd520
已完成
3 期
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURESEpilepsy with partial onset seizures10039911NL-OMON39878Pfizer3
进行中(未招募)
1 期
A safety and efficacy study of pregabalin in children 4-16 years of age for partial onset seizuresPartial onset seizuresMedDRA version: 14.1Level: LLTClassification code 10034089Term: Partial seizures NOSSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020852-79-GRPfizer Inc.235 East 42nd Street, New York, NY 10017225
